Harnessing Regulatory T Cells to Establish Immune Tolerance

Overview

Journal Sci Transl Med

Specialties General Medicine
Science

Date 2024 Mar 13

PMID 38478632

Authors

Patrick Ho

Ellen Cahir-McFarland

Jason D Fontenot

Tracey Lodie

Adel Nada

Qizhi Tang

Laurence A Turka

Jeffrey A Bluestone

Affiliations

Soon will be listed here.

Abstract

Engineered regulatory T (T) cells have emerged as precision therapeutics aimed at inducing immune tolerance while reducing the risks associated with generalized immunosuppression. This Viewpoint highlights the opportunities and challenges for engineered T cell therapies in treating autoimmune and other inflammatory diseases.

Citing Articles

Molecular Hydrogen as an Adjuvant Therapy in Severe Lupus Serositis With Heart Failure: A Case Report on Immune Modulation and Fatigue Reduction.

Lin Y, Lu J, Ho Y, Lui S, Hsieh T, Liu H In Vivo. 2025; 39(2):1200-1206.

PMID: 40010949 PMC: 11884437. DOI: 10.21873/invivo.13924.

The Role of Deregulated MicroRNAs in Immune Cells of Sjögren's Disease.

Han Q, Gao L, Chen L Int J Gen Med. 2025; 18:847-855.

PMID: 39990298 PMC: 11846509. DOI: 10.2147/IJGM.S504780.

Metabolic reprogramming of naïve regulatory T cells by IL-7 and IL-15 promotes their persistence and performance upon adoptive transfer.

Filoni J, Ferrari A, Jofra T, Putignano A, Da Dalt L, Cesarano S Commun Biol. 2025; 8(1):99.

PMID: 39838096 PMC: 11751088. DOI: 10.1038/s42003-024-07381-1.

CAR-based cell therapies for systemic lupus erythematosus.

Wang Y, Lu L, Ye S, Fu Q Chin Med J (Engl). 2024; .

PMID: 39682021 PMC: 11882275. DOI: 10.1097/CM9.0000000000003406.

Antigen-specific immunotherapies for autoimmune disease.

Buckner J Nat Rev Rheumatol. 2024; 21(2):88-97.

PMID: 39681709 DOI: 10.1038/s41584-024-01201-w.